Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2025-12-25 @ 9:30 PM
NCT ID:
NCT02706951
Pre Assignment Details:
Participants were randomized in a 2:2:1:1 ratio to 1 of 4 groups:
* Upadacitinib 30 mg (Periods 1 and 2)
* Upadacitinib 15 mg (Periods 1 and 2)
* MTX (Period 1) → upadacitinib 30 mg (Period 2)
* MTX (Period 1) → upadacitinib 15 mg (Period 2)
Randomization was stratified by geographic region. The MTX groups were pooled for Week 14 analyses.
Starting with Amend. 5 \& during Period 2, all participants received open-label upadacitinib 15 mg, including participants receiving upadacitinib 30 mg
Recruitment Details:
A total of 648 participants with rheumatoid arthritis (RA) on a stable dose of methotrexate (MTX) were randomized at 138 study sites located in 24 countries.
Study:
NCT02706951
Study Brief:
Results Section:
NCT02706951